Back

cGAS-mediated IFN-I signaling contributes to disease progression in drug-refractory epilepsy

Huang, Y.; Fan, L.; Wong, M. Y.; Lei, Z.; Krishnamachary, B.; Zhu, D.; Cadiz, M.; Nagiri, R. K.; Ye, P.; Norman, K.; Bhagwat, M.; Lee, Y. J.; Li, H.; Zhu, J.; Amin, S.; Lauderdale, K.; Chen, H.; Luo, W.; Gong, S.; Liechty, B. L.; Palop, J. J.; Sinha, S. C.; Wu, J.; Zhao, M.; Gan, L.

2026-02-02 neuroscience
10.64898/2026.01.30.702860 bioRxiv
Show abstract

Epilepsy is a prevalent neurological disease with a third of patients becoming non-responsive to antiepileptic drugs and developing drug-refractory epilepsy (DRE). Here we report that DRE disease progression is contributed by overactive cyclic GMP-AMP synthase (cGAS), a double-stranded DNA sensor that induces type I interferon (IFN-I) signaling. In human DRE microglia, we observe a robust IFN-I signature and the activation of upstream cGAS-STING signaling. Further, in mouse models of Dravet syndrome, a genetic form of DRE, we observe the activation of the cGAS pathway. We show that microglial cGAS can be activated by DNA released from hyperexcitable neurons. Genetic reduction and pharmacological inhibition of cGAS reduces epileptic phenotypes, glial inflammatory signatures, and neuronal transcriptomic changes, underscoring the therapeutic potential of targeting cGAS for DRE treatment.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.